![Page 1: Results:Inhaled Insulin Phase II Trials Summary](https://reader033.vdocuments.net/reader033/viewer/2022051506/58874a1e1a28aba76b8ba2f2/html5/thumbnails/1.jpg)
Are We There Yet?
Eda Cengiz, MD, MHSAssistant Professor of Pediatrics
Yale University School of Medicine
Update on Artificial Pancreas Project
![Page 2: Results:Inhaled Insulin Phase II Trials Summary](https://reader033.vdocuments.net/reader033/viewer/2022051506/58874a1e1a28aba76b8ba2f2/html5/thumbnails/2.jpg)
Artificial Pancreas / Bionic Pancreas ?
utilizing electronic devices and mechanical parts to assist humans in performing difficult,
dangerous, or intricate tasks, as by supplementing or duplicating parts of the body
Artificial intelligence runs the algorithm
![Page 3: Results:Inhaled Insulin Phase II Trials Summary](https://reader033.vdocuments.net/reader033/viewer/2022051506/58874a1e1a28aba76b8ba2f2/html5/thumbnails/3.jpg)
•Sensor signals transmitted to a laptop computer that displays the sensor glucose and calculates rate of insulin delivery
•Rate of insulin delivery is transmitted to the insulin pump
Determine insulin requirement real time, deliver proper insulin to achieve euglycemia.
The Promise of Artificial Pancreas
•Glucose Sensor•Algorithm•Insulin Pump & Insulin
![Page 4: Results:Inhaled Insulin Phase II Trials Summary](https://reader033.vdocuments.net/reader033/viewer/2022051506/58874a1e1a28aba76b8ba2f2/html5/thumbnails/4.jpg)
Medtronic Closed-loop System c. 2011
Insulin Pump
CGM
Laptop Controller
![Page 5: Results:Inhaled Insulin Phase II Trials Summary](https://reader033.vdocuments.net/reader033/viewer/2022051506/58874a1e1a28aba76b8ba2f2/html5/thumbnails/5.jpg)
What is taking so long ?
During a Typical Clinic Visit at Yale Diabetes Center…
How is it going with the Artificial Pancreas Dr. C?
When is it going to be ready?
![Page 6: Results:Inhaled Insulin Phase II Trials Summary](https://reader033.vdocuments.net/reader033/viewer/2022051506/58874a1e1a28aba76b8ba2f2/html5/thumbnails/6.jpg)
Challenges & Solutions: Artificial Pancreas (Closed-Loop System)
•Progress to date
•Pitfalls
•Solutions
•Future closed-loop studies(hot off the press!)
![Page 7: Results:Inhaled Insulin Phase II Trials Summary](https://reader033.vdocuments.net/reader033/viewer/2022051506/58874a1e1a28aba76b8ba2f2/html5/thumbnails/7.jpg)
JDRF Road Map to Artificial Pancreas
What is the plan?
![Page 8: Results:Inhaled Insulin Phase II Trials Summary](https://reader033.vdocuments.net/reader033/viewer/2022051506/58874a1e1a28aba76b8ba2f2/html5/thumbnails/8.jpg)
Artificial Pancreas
Do we need to wait until we have the Fully Automated Artificial Pancreas?
![Page 9: Results:Inhaled Insulin Phase II Trials Summary](https://reader033.vdocuments.net/reader033/viewer/2022051506/58874a1e1a28aba76b8ba2f2/html5/thumbnails/9.jpg)
Artificial Pancreas
Progress to date
SENSOR-AUGMENTED PUMP THERAPY
![Page 10: Results:Inhaled Insulin Phase II Trials Summary](https://reader033.vdocuments.net/reader033/viewer/2022051506/58874a1e1a28aba76b8ba2f2/html5/thumbnails/10.jpg)
CGM improved A1c, but not in everyone
-0.6
-0.5
-0.4
-0.3
-0.2
-0.1
0
0.1
8 - 14 yrs 15 - 24 yrs > 25 yrs
RT-CGM Control
p=0.29 p=0.52 p<0.001
JDRF CGM Study Group. N Engl J Med 2008; 359:1464-76.
![Page 11: Results:Inhaled Insulin Phase II Trials Summary](https://reader033.vdocuments.net/reader033/viewer/2022051506/58874a1e1a28aba76b8ba2f2/html5/thumbnails/11.jpg)
Average Days of CGM Use by Age Group
CGM Use
0%
20%
40%
60%
80%
Age ≥25 Age 15-24 Age 8-14
Per
cent
age
of s
ubje
cts
<4.0 days/week
4.0-<6.0 days/week
≥6.0 days/week
Change in glycated hemoglobin-0.8
-0.6
-0.4
-0.2
0.0
0.2
Cha
nge
in g
lyca
ted
hem
oglo
bin
JDRF CGM Study Group. N Engl J Med 2008; 359:1464-76.
![Page 12: Results:Inhaled Insulin Phase II Trials Summary](https://reader033.vdocuments.net/reader033/viewer/2022051506/58874a1e1a28aba76b8ba2f2/html5/thumbnails/12.jpg)
Bergenstal RM, Tamborlane WV, Ahmann A, et al. N Engl J Med. Doi:10.1056/NEJMoa1002853.
8.3%
7.3%
7.5% 7.5% 7.5%
8.0% 8.0%8.1% 8.1%
7.0%
7.5%
8.0%
8.5%
0 3 6 9 12
Months
A1C
Medtronic STAR 3 Sensor-Augmented Pump Trial
Values are means ± SE. Comparisons between SAP group and MDI group are significant for each time period (P<0.001).
• The SAP group achieved a greater A1C reduction vs. MDI at 3 months and sustained it over 12 months
A1C Reduction for SAP and MDI Groups
= MDI= SAPn = 244 n = 241
- 0.6P<0.001
∆ -0.2
∆ -0.8
- 0.6P<0.001
![Page 13: Results:Inhaled Insulin Phase II Trials Summary](https://reader033.vdocuments.net/reader033/viewer/2022051506/58874a1e1a28aba76b8ba2f2/html5/thumbnails/13.jpg)
Bergenstal RM, Tamborlane WV, Ahmann A, et al. N Engl J Med. Doi:10.1056/NEJMoa1002853.
A1C Reduction Correlates to Increased Sensor Use
Values are the difference between the means ± SE. p=0.003 for association between sensor wear and A1C reduction at 1 year. Only 7 participants had sensor use of 20% or less, with a change in A1C of -0.43 at 1 year vs. baseline.
• The majority of patients used sensors ≥61% of the time • Patients who used sensors ≥81% of the time reduced their mean A1C by
1.2% at 1 year vs. baseline
-0.19
-0.64-0.79
-1.21-1.5
-1
-0.5
021-40% 41-60% 61-80% 81-100%
Frequency of Sensor Use (% of Time)
Cha
nge
in A
1C a
t 1 Y
ear v
s B
asel
ine
n =27 n =46 n =108 n =56
![Page 14: Results:Inhaled Insulin Phase II Trials Summary](https://reader033.vdocuments.net/reader033/viewer/2022051506/58874a1e1a28aba76b8ba2f2/html5/thumbnails/14.jpg)
DirecNet / TrialNet Metabolic Control Study
• Does the rapid normalization of BG levels at the time of diagnosis of diabetes, followed by super-intensive control of BG levels, help to preserve residual beta-cell function?
• Use of an artificial pancreas in subjects AT DIAGNOSIS for 3-4 days to rapidly normalize BG levels, followed by sensor-augmented pump therapy x 2 years
![Page 15: Results:Inhaled Insulin Phase II Trials Summary](https://reader033.vdocuments.net/reader033/viewer/2022051506/58874a1e1a28aba76b8ba2f2/html5/thumbnails/15.jpg)
Sensor and BG Levels During CL TherapySensor and BG Levels During CL Therapy
![Page 16: Results:Inhaled Insulin Phase II Trials Summary](https://reader033.vdocuments.net/reader033/viewer/2022051506/58874a1e1a28aba76b8ba2f2/html5/thumbnails/16.jpg)
Mean Sensor Glucose Levels Prior to, Mean Sensor Glucose Levels Prior to, During, and Following CL TherapyDuring, and Following CL Therapy
![Page 17: Results:Inhaled Insulin Phase II Trials Summary](https://reader033.vdocuments.net/reader033/viewer/2022051506/58874a1e1a28aba76b8ba2f2/html5/thumbnails/17.jpg)
3 mth f/u: A1c = 5.9 %
6 wk f/u
![Page 18: Results:Inhaled Insulin Phase II Trials Summary](https://reader033.vdocuments.net/reader033/viewer/2022051506/58874a1e1a28aba76b8ba2f2/html5/thumbnails/18.jpg)
6 wk f/u6 mth f/u: A1c = 6.0 %
“typical” tracing12 mth f/u: A1c = 6.3 %
![Page 19: Results:Inhaled Insulin Phase II Trials Summary](https://reader033.vdocuments.net/reader033/viewer/2022051506/58874a1e1a28aba76b8ba2f2/html5/thumbnails/19.jpg)
Artificial Pancreas
Progress to Date
SENSOR-AUGMENTED PUMP THERAPY
PUMP SUSPENSION FORACTUAL
HYPOGLYCEMIA
![Page 20: Results:Inhaled Insulin Phase II Trials Summary](https://reader033.vdocuments.net/reader033/viewer/2022051506/58874a1e1a28aba76b8ba2f2/html5/thumbnails/20.jpg)
Prevention of Hypoglycemia with AP
• Insulin suspension prevented low BG (<60mg/dl) in 78% of the suspensions.
• Non resulted in hyperglycemia
• Reduction in CGM hypoglycemia alarms
![Page 21: Results:Inhaled Insulin Phase II Trials Summary](https://reader033.vdocuments.net/reader033/viewer/2022051506/58874a1e1a28aba76b8ba2f2/html5/thumbnails/21.jpg)
A Semi-Closed-Loop System: The Paradigm® Veo™*
• Integrated sensor• Improved Calibration Routines• Glucose trend• Alarms
– Outside target zone– Predictive– Missing insulin bolus
• Minimum basal rate of 0.025 U/h• Hypoglycemia suspend
– Suspend for 2 hours– Re-suspend after 4 hours if
needed
* Investigational device. Limited by U.S. law to investigational use.
Keenan et al., J. Diabetes Sci. Tech., 2010; 4(1):111-118Buckingham et al., Diabetes Technol. Ther., 2009; 11:93-97Attia et al., Diabetes Care, 1998; 21:817-821.Guerci et al., J Clin Endocrinol Metab, 1999; 84:2673-2678.Zisser, Diabetes Care, 2008; 31:238-239.
![Page 22: Results:Inhaled Insulin Phase II Trials Summary](https://reader033.vdocuments.net/reader033/viewer/2022051506/58874a1e1a28aba76b8ba2f2/html5/thumbnails/22.jpg)
S L I D E 22
Automatic Low-Glucose Suspend
LGS off LGS onMean Glucose (mg/dL) 145 ± 23 148 ± 19
Time < 70 per day (min) 101 ± 68 58 ± 33 *
Time > 140 per day (min) 651 ± 240 639 ± 182
Number of excursions < 70 and < 40 mg/dL reduced with LGS
* p=0.002
Danne T, Diabetes Technol Ther 2011; 13: 1129-1134
![Page 23: Results:Inhaled Insulin Phase II Trials Summary](https://reader033.vdocuments.net/reader033/viewer/2022051506/58874a1e1a28aba76b8ba2f2/html5/thumbnails/23.jpg)
Artificial Pancreas
SENSOR-AUGMENTED PUMP THERAPY
PUMP SUSPENSION FORACTUAL HYPOGLYCEMIA
PUMP SUSPENSION FORPREDICTED
HYPOGLYCEMIA
Progress to Date
![Page 24: Results:Inhaled Insulin Phase II Trials Summary](https://reader033.vdocuments.net/reader033/viewer/2022051506/58874a1e1a28aba76b8ba2f2/html5/thumbnails/24.jpg)
CL2-MW 9/3/08
Time in Minutes Beginning at 9:30 PM
0 100 200 300 400 500 600
Ser
um G
luco
se (m
g/dl
)
20
40
60
80
100
120
140
160
Y A
xis
2
0.0
0.5
1.0
1.5
2.0
Controller GlucoseYSI Basal Insulin
ROC = -.36 mg/dl-min3 Alarm, Threshold 80 mg/dl, Horizon 35 minAutomatic pump suspension for predicted hypoglycemia
![Page 25: Results:Inhaled Insulin Phase II Trials Summary](https://reader033.vdocuments.net/reader033/viewer/2022051506/58874a1e1a28aba76b8ba2f2/html5/thumbnails/25.jpg)
Exercise AP Study objective
• To evaluate whether use of a AP system reduces the risk of delayed (nocturnal) hypoglycemia following antecedent daytime exercise
![Page 26: Results:Inhaled Insulin Phase II Trials Summary](https://reader033.vdocuments.net/reader033/viewer/2022051506/58874a1e1a28aba76b8ba2f2/html5/thumbnails/26.jpg)
Subject recruitment, consent, enrollment
(n = 12)
Closed-Loop
Open-LoopOpen-Loop
Closed-Loop
Exercise Study Protocol Schematic
48-hour evaluation period2 overnights
48-hour evaluation period2 overnights
Plasma BG q30 min, insulin q30 min x 3h @ meals
![Page 27: Results:Inhaled Insulin Phase II Trials Summary](https://reader033.vdocuments.net/reader033/viewer/2022051506/58874a1e1a28aba76b8ba2f2/html5/thumbnails/27.jpg)
Nocturnal Hypoglycemia
Closed LoopOpen Loop
0
5
10
15
20
25
3
22
All Nocturnal Hypo
Num
ber
of T
reat
men
ts G
iven
p=0.05
1
14
Night Following Exercise
p=0.06
![Page 28: Results:Inhaled Insulin Phase II Trials Summary](https://reader033.vdocuments.net/reader033/viewer/2022051506/58874a1e1a28aba76b8ba2f2/html5/thumbnails/28.jpg)
Glucose Frequency DistributionNight after sedentary condition
1 % 99 % 0% 3 % 90 % 7 %
P<0.0001
![Page 29: Results:Inhaled Insulin Phase II Trials Summary](https://reader033.vdocuments.net/reader033/viewer/2022051506/58874a1e1a28aba76b8ba2f2/html5/thumbnails/29.jpg)
3 % 93 % 4 %8 % 76 % 16 %
P<0.0001
Glucose Frequency DistributionNight following afternoon exercise
![Page 30: Results:Inhaled Insulin Phase II Trials Summary](https://reader033.vdocuments.net/reader033/viewer/2022051506/58874a1e1a28aba76b8ba2f2/html5/thumbnails/30.jpg)
Artificial Pancreas
SENSOR-AUGMENTED PUMP THERAPY
PUMP SUSPENSION FORACTUAL HYPOGLYCEMIA
PUMP SUSPENSION FORPREDICTED HYPOGLYCEMIA
BASAL/BOLUS ACTIVATION
FOR HYPERGLYCEMIA
Progress to Date
![Page 31: Results:Inhaled Insulin Phase II Trials Summary](https://reader033.vdocuments.net/reader033/viewer/2022051506/58874a1e1a28aba76b8ba2f2/html5/thumbnails/31.jpg)
Conceptual Scheme for “Treat-to-Range”
![Page 32: Results:Inhaled Insulin Phase II Trials Summary](https://reader033.vdocuments.net/reader033/viewer/2022051506/58874a1e1a28aba76b8ba2f2/html5/thumbnails/32.jpg)
![Page 33: Results:Inhaled Insulin Phase II Trials Summary](https://reader033.vdocuments.net/reader033/viewer/2022051506/58874a1e1a28aba76b8ba2f2/html5/thumbnails/33.jpg)
Artificial Pancreas
Progress to Date
SENSOR-AUGMENTED PUMP THERAPY
PUMP SUSPENSION FORACTUAL HYPOGLYCEMIA
PUMP SUSPENSION FORPREDICTED HYPOGLYCEMIA
BASAL/BOLUS ACTIVATIONFOR HYPERGLYCEMIA
CLOSED-LOOP BASAL
MANUAL MEALS
![Page 34: Results:Inhaled Insulin Phase II Trials Summary](https://reader033.vdocuments.net/reader033/viewer/2022051506/58874a1e1a28aba76b8ba2f2/html5/thumbnails/34.jpg)
Studies of Overnight CL
• Increased time in target BG
• Reduction of hypoglycemia
• Incorporation of daytime challenges– Exercise– Alcohol– Pregnancy
![Page 35: Results:Inhaled Insulin Phase II Trials Summary](https://reader033.vdocuments.net/reader033/viewer/2022051506/58874a1e1a28aba76b8ba2f2/html5/thumbnails/35.jpg)
Hybrid control improves performance
6A Noon 6P MidN 6A Noon 6P0
100
200
300Closed Loop (N=8)
meals
setpoint
Hybrid CL (N=9)
Glu
cose
(mg/
dl)
Mean Daytime Peak PPFull CL 147 58 154 60 219 54Hybrid 138 49 143 50 196 52
Weinzimer SA. Diabetes Care 2008; 31:934-939.
![Page 36: Results:Inhaled Insulin Phase II Trials Summary](https://reader033.vdocuments.net/reader033/viewer/2022051506/58874a1e1a28aba76b8ba2f2/html5/thumbnails/36.jpg)
Late post-prandial hypoglycemia in CL
6 12 18 24 30 36 420
3
6
9
12
15
18
0
50
100
150
Plasma InsulinEVP
Insu
lin (U
/h)
Insulin ( U/ml)
6 12 18 24 30 36 420
100
200
300
0
25
50
SG CHO
Glu
cose
(mg/
dl)
![Page 37: Results:Inhaled Insulin Phase II Trials Summary](https://reader033.vdocuments.net/reader033/viewer/2022051506/58874a1e1a28aba76b8ba2f2/html5/thumbnails/37.jpg)
Artificial Pancreas
Progress to date
SENSOR-AUGMENTED PUMP THERAPY
PUMP SUSPENSION FORACTUAL HYPOGLYCEMIA
PUMP SUSPENSION FORPREDICTED HYPOGLYCEMIA
BASAL/BOLUS ACTIVATIONFOR HYPERGLYCEMIA
CLOSED-LOOP MULTIHORMONAL
FULL CLOSED-LOOP CONTROL
CLOSED-LOOP BASALMANUAL MEALS
![Page 38: Results:Inhaled Insulin Phase II Trials Summary](https://reader033.vdocuments.net/reader033/viewer/2022051506/58874a1e1a28aba76b8ba2f2/html5/thumbnails/38.jpg)
AP Multi-hormonal Approach
• Can the addition of pramlintide improve the performance of a CL system by reducing the peak post-prandial glucose excursions?
![Page 39: Results:Inhaled Insulin Phase II Trials Summary](https://reader033.vdocuments.net/reader033/viewer/2022051506/58874a1e1a28aba76b8ba2f2/html5/thumbnails/39.jpg)
Pramlintide
• Analog of human amylin
• Co-secreted with insulin from -cell
• Used as adjunct to insulin in T1D to reduce post-prandial glycemic excursions
– Delay gastric emptying– Suppress endogenous glucagon
![Page 40: Results:Inhaled Insulin Phase II Trials Summary](https://reader033.vdocuments.net/reader033/viewer/2022051506/58874a1e1a28aba76b8ba2f2/html5/thumbnails/40.jpg)
Subject recruitment, consent, enrollment
(n = 8)
Closed-Loop
Closed-Loop + Pramlintide
(30 mcg per meal)
Closed-Loop + Pramlintide
(30 mcg per meal)
Closed-Loop
Pramlintide Study Protocol Schematic
24-hour evaluation period3 meals (BF, L, Din)
24-hour evaluation period3 meals (BF, L, Din)
Plasma BG q30 min, insulin q30 min x 3h @ meals
![Page 41: Results:Inhaled Insulin Phase II Trials Summary](https://reader033.vdocuments.net/reader033/viewer/2022051506/58874a1e1a28aba76b8ba2f2/html5/thumbnails/41.jpg)
Glucose excursions with/without pramlintide
6 9 12 15 18 21 24 27 30 330
100
200
300
Control DaySymlin Day
Time (hrs)
Blo
od G
luco
se (m
g/dL
)
![Page 42: Results:Inhaled Insulin Phase II Trials Summary](https://reader033.vdocuments.net/reader033/viewer/2022051506/58874a1e1a28aba76b8ba2f2/html5/thumbnails/42.jpg)
Summary and conclusions
• Pramlintide had modest effect on prandial glucose
• Would require manual injection or at best, manual bolus
• Faster insulin absorption / action clearly needed
![Page 43: Results:Inhaled Insulin Phase II Trials Summary](https://reader033.vdocuments.net/reader033/viewer/2022051506/58874a1e1a28aba76b8ba2f2/html5/thumbnails/43.jpg)
Artificial Pancreas
Progress to date
SENSOR-AUGMENTED PUMP THERAPY
PUMP SUSPENSION FORACTUAL HYPOGLYCEMIA
PUMP SUSPENSION FORPREDICTED HYPOGLYCEMIA
BASAL/BOLUS ACTIVATIONFOR HYPERGLYCEMIA
CLOSED-LOOP MULTIHORMONAL
FULL CLOSED-LOOP CONTROL
CLOSED-LOOP BASALMANUAL MEALS
?
![Page 44: Results:Inhaled Insulin Phase II Trials Summary](https://reader033.vdocuments.net/reader033/viewer/2022051506/58874a1e1a28aba76b8ba2f2/html5/thumbnails/44.jpg)
What do we need to achieve AP?
• Better accuracy, user interface, reliability.
• Better algorithm• One site for CGM &
Insulin
![Page 45: Results:Inhaled Insulin Phase II Trials Summary](https://reader033.vdocuments.net/reader033/viewer/2022051506/58874a1e1a28aba76b8ba2f2/html5/thumbnails/45.jpg)
Single Port, Multiple Sensor
• One site, two catheters for insulin infusion and glucose sensing
• Single port for CGM and insulin
• CGM with an optic sensor back up
![Page 46: Results:Inhaled Insulin Phase II Trials Summary](https://reader033.vdocuments.net/reader033/viewer/2022051506/58874a1e1a28aba76b8ba2f2/html5/thumbnails/46.jpg)
What do we need to achieve AP?
• Better accuracy, user interface, reliability.
• Better algorithm• One site for CGM &
Insulin
• Faster acting insulin
![Page 47: Results:Inhaled Insulin Phase II Trials Summary](https://reader033.vdocuments.net/reader033/viewer/2022051506/58874a1e1a28aba76b8ba2f2/html5/thumbnails/47.jpg)
Dangerous Delays in Insulin Action after SC Injection
1. Delays due to the chemical properties of insulin.
1. Tissue delays
![Page 48: Results:Inhaled Insulin Phase II Trials Summary](https://reader033.vdocuments.net/reader033/viewer/2022051506/58874a1e1a28aba76b8ba2f2/html5/thumbnails/48.jpg)
Insulin Time-Action Curves
0 30 60 90 120 150 180 210 240 270 3000
10
20
30
40
50
60
70
80
90
100
0
1
2
3
4
5
6
7
InsulinGIR
Time (min)
Plas
ma
Insu
lin (u
U/m
L) GIR
(mg/kg/m
in)
![Page 49: Results:Inhaled Insulin Phase II Trials Summary](https://reader033.vdocuments.net/reader033/viewer/2022051506/58874a1e1a28aba76b8ba2f2/html5/thumbnails/49.jpg)
•The InsuPatchTM device applies controlled heat around the insulin infusion site.
InsuPatch
Temp. Sensor
![Page 50: Results:Inhaled Insulin Phase II Trials Summary](https://reader033.vdocuments.net/reader033/viewer/2022051506/58874a1e1a28aba76b8ba2f2/html5/thumbnails/50.jpg)
with InsuPatch activation:
Aspart insulin bolus maximum effect was 35 min earlier compared
to the same dose bolus without InsuPatch activation .
Peak aspart insulin action curve shifted to the left .
The Effect of InsuPatch on The Effect of InsuPatch on Insulin Action Insulin Action
![Page 51: Results:Inhaled Insulin Phase II Trials Summary](https://reader033.vdocuments.net/reader033/viewer/2022051506/58874a1e1a28aba76b8ba2f2/html5/thumbnails/51.jpg)
51
Hyaluronidase Mechanism of Action
![Page 52: Results:Inhaled Insulin Phase II Trials Summary](https://reader033.vdocuments.net/reader033/viewer/2022051506/58874a1e1a28aba76b8ba2f2/html5/thumbnails/52.jpg)
The Accu-Chek DiaPort is a port system for continuous intraperitoneal insulin infusion.
DiaPort
The catheter tip is placed in the peritoneal cavity where the insulin is directly infused.
![Page 53: Results:Inhaled Insulin Phase II Trials Summary](https://reader033.vdocuments.net/reader033/viewer/2022051506/58874a1e1a28aba76b8ba2f2/html5/thumbnails/53.jpg)
Pathway to Closed-Loop (CL)
![Page 54: Results:Inhaled Insulin Phase II Trials Summary](https://reader033.vdocuments.net/reader033/viewer/2022051506/58874a1e1a28aba76b8ba2f2/html5/thumbnails/54.jpg)
Pump
Platform and Connectivity for Ambulatory Studies
![Page 55: Results:Inhaled Insulin Phase II Trials Summary](https://reader033.vdocuments.net/reader033/viewer/2022051506/58874a1e1a28aba76b8ba2f2/html5/thumbnails/55.jpg)
Artificial Pancreas
Progress to date
SENSOR-AUGMENTED PUMP THERAPY
PUMP SUSPENSION FORACTUAL HYPOGLYCEMIA
PUMP SUSPENSION FORPREDICTED HYPOGLYCEMIA
BASAL/BOLUS ACTIVATIONFOR HYPERGLYCEMIA
CLOSED-LOOP MULTIHORMONAL
FULL CLOSED-LOOP CONTROL
CLOSED-LOOP BASALMANUAL MEALS
?Outpatient studies
![Page 56: Results:Inhaled Insulin Phase II Trials Summary](https://reader033.vdocuments.net/reader033/viewer/2022051506/58874a1e1a28aba76b8ba2f2/html5/thumbnails/56.jpg)
![Page 57: Results:Inhaled Insulin Phase II Trials Summary](https://reader033.vdocuments.net/reader033/viewer/2022051506/58874a1e1a28aba76b8ba2f2/html5/thumbnails/57.jpg)
The “Dream” Study
• http://www.youtube.com/watch?v=9HMx8yy2nVw
![Page 58: Results:Inhaled Insulin Phase II Trials Summary](https://reader033.vdocuments.net/reader033/viewer/2022051506/58874a1e1a28aba76b8ba2f2/html5/thumbnails/58.jpg)
Thank you!
• Yale Closed Loop Team– Stu Weinzimer– Jennifer Sherr– William Tamborlane– Grace Kim– Miladys Palau– Camille Michaud– Lori Carria– Amy Steffen– Kate Weyman– Melinda Zgorski– Eileen Tichy